Herbert Irving Comprehensive Cancer Center
Benjamin Izar, MD

Benjamin Izar, MD, PhD, has been named a Schaefer Research Scholar, an annual award that goes to four leading Columbia University scientists “whose current work is of outstanding merit with significant academic distinction.” Each awardee will receive a $50,000 cash prize and up to $200,000 in direct research support.

Dr. Izar is an assistant professor of medicine at Columbia's Vagelos College of Physicians and Surgeons and member of the Tumor Biology Microenvironment research program at the Herbert Irving Comprehensive Cancer Center. His research explores drug resistance and aims to understand underlying mechanisms in the context of targeted cancer therapies and immunotherapies.

Dr. Izar has received several recent honors for his innovative research, including a 2020 Gerstner Scholar, a V Scholar award, and a Velocity fellowship.

Clinical Studies Managed By This Investigator:
Condition Study Title
Cancer [ CLOSED ] Study of COM701 Alone and in Combination with Nivolumain in Patients with Advanced Solid Tumors (Breast Cancer/Ovarian Cancer/Lung Cancer)
Cancer A Study in Subjects With Advanced Cancer
Cancer Study of IMC-F106C Alone and in Combination With Checkpoint Inhibitors in Participants with Advanced Cancers
Melanoma CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
Cancer [ CLOSED ] COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors
Cancer A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Cancer
Melanoma Study of ALKS 4230 in Patients with Previously Treated Advanced Melanoma
Cancer Study of STK-012 Alone or in Combination with Pembrolizumab (KEYTRUDA) in Patients with Advanced Solid Tumors